Aligos Therapeuticsinc Stock Buy Hold or Sell Recommendation
| ALGS Stock | USD 0.75 0.04 5.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Aligos TherapeuticsInc is 'Strong Sell'. Macroaxis provides Aligos TherapeuticsInc buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ALGS positions. The advice algorithm takes into account all of Aligos TherapeuticsInc's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Aligos TherapeuticsInc's buy or sell advice are summarized below:
Real Value 1.57 | Target Price 4 | Hype Value 0.73 | Market Value 0.75 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Aligos TherapeuticsInc given historical horizon and risk tolerance towards Aligos TherapeuticsInc. When Macroaxis issues a 'buy' or 'sell' recommendation for Aligos TherapeuticsInc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Aligos |
Execute Aligos TherapeuticsInc Buy or Sell Advice
The Aligos recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Aligos TherapeuticsInc. Macroaxis does not own or have any residual interests in Aligos TherapeuticsInc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Aligos TherapeuticsInc's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Aligos TherapeuticsInc Trading Alerts and Improvement Suggestions
| Aligos TherapeuticsInc had very high historical volatility over the last 90 days | |
| Aligos TherapeuticsInc has some characteristics of a very speculative penny stock | |
| Aligos TherapeuticsInc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.53 M. Net Loss for the year was (87.68 M) with loss before overhead, payroll, taxes, and interest of (71.17 M). | |
| Aligos TherapeuticsInc currently holds about 159.34 M in cash with (79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Vanguard Group Inc. Increases Stock Position in Aligos Therapeutics, Inc. - Defense World |
Aligos TherapeuticsInc Returns Distribution Density
The distribution of Aligos TherapeuticsInc's historical returns is an attempt to chart the uncertainty of Aligos TherapeuticsInc's future price movements. The chart of the probability distribution of Aligos TherapeuticsInc daily returns describes the distribution of returns around its average expected value. We use Aligos TherapeuticsInc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Aligos TherapeuticsInc returns is essential to provide solid investment advice for Aligos TherapeuticsInc.
| Mean Return | 0.31 | Value At Risk | -6.25 | Potential Upside | 8.51 | Standard Deviation | 5.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Aligos TherapeuticsInc historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Aligos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aligos TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aligos TherapeuticsInc backward and forwards among themselves. Aligos TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Aligos TherapeuticsInc's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2023-12-31 | 1.1 M | Vanguard Group Inc | 2023-12-31 | 1 M | Pivotal Bioventure Partners Investment Advisor Llc | 2023-12-31 | 743.2 K | Silverarc Capital Management, Llc | 2023-12-31 | 668.5 K | Acadian Asset Management Llc | 559.4 K | Renaissance Technologies Corp | 2023-12-31 | 490 K | Geode Capital Management, Llc | 2023-12-31 | 321 K | Blackrock Inc | 2023-12-31 | 296.1 K | State Street Corporation | 2023-12-31 | 97.4 K | Armistice Capital, Llc | 2023-12-31 | 6.8 M | Ecor1 Capital, Llc | 2023-12-31 | 6.4 M |
Aligos TherapeuticsInc Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 6.8M | 32.8M | 3.9M | (25.4M) | 45.0M | 47.2M | |
| Change In Cash | 45.6M | 150.8M | (34.0M) | (105.5M) | 54.3M | 57.0M | |
| Net Borrowings | (43K) | (58K) | (79K) | (61K) | (54.9K) | (52.2K) | |
| Free Cash Flow | (49.6M) | (76.3M) | (116.6M) | (80.3M) | (79.0M) | (83.0M) | |
| Depreciation | 2.3M | 3.3M | 3.8M | 3.7M | 3.1M | 3.2M | |
| Other Non Cash Items | (1.2M) | 11.4M | 86K | (159K) | 267K | 253.7K | |
| Capital Expenditures | 2.8M | 2.1M | 892K | 943K | 19K | 18.1K | |
| Net Income | (52.3M) | (108.5M) | (128.3M) | (96.0M) | (87.7M) | (92.1M) | |
| End Period Cash Flow | 70.1M | 220.9M | 187.0M | 81.5M | 135.8M | 132.0M | |
| Change To Netincome | (473K) | 14.9M | 13.5M | 14.7M | 16.9M | 9.7M |
Aligos TherapeuticsInc Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Aligos TherapeuticsInc or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Aligos TherapeuticsInc's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Aligos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.17 | |
β | Beta against NYSE Composite | 2.25 | |
σ | Overall volatility | 5.70 | |
Ir | Information ratio | 0.04 |
Aligos TherapeuticsInc Volatility Alert
Aligos TherapeuticsInc exhibits above-average semi-deviation for your current time horizon. Aligos TherapeuticsInc is a potential penny stock. Although Aligos TherapeuticsInc may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Aligos TherapeuticsInc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Aligos instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Aligos TherapeuticsInc Fundamentals Vs Peers
Comparing Aligos TherapeuticsInc's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aligos TherapeuticsInc's direct or indirect competition across all of the common fundamentals between Aligos TherapeuticsInc and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aligos TherapeuticsInc or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Aligos TherapeuticsInc's fundamental indicators could also be used in its relative valuation, which is a method of valuing Aligos TherapeuticsInc by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Aligos TherapeuticsInc to competition |
| Fundamentals | Aligos TherapeuticsInc | Peer Average |
| Return On Equity | -0.89 | -0.31 |
| Return On Asset | -0.37 | -0.14 |
| Operating Margin | (9.43) % | (5.51) % |
| Current Valuation | (65.01 M) | 16.62 B |
| Shares Outstanding | 72.58 M | 571.82 M |
| Shares Owned By Insiders | 21.07 % | 10.09 % |
| Shares Owned By Institutions | 62.52 % | 39.21 % |
| Number Of Shares Shorted | 868.83 K | 4.71 M |
| Price To Book | 0.82 X | 9.51 X |
| Price To Sales | 4.87 X | 11.42 X |
| Revenue | 15.53 M | 9.43 B |
| Gross Profit | (71.17 M) | 27.38 B |
| EBITDA | (84.36 M) | 3.9 B |
| Net Income | (87.68 M) | 570.98 M |
| Cash And Equivalents | 159.34 M | 2.7 B |
| Cash Per Share | 3.72 X | 5.01 X |
| Total Debt | 11.14 M | 5.32 B |
| Debt To Equity | 0.1 % | 48.70 % |
| Current Ratio | 5.30 X | 2.16 X |
| Book Value Per Share | 1.23 X | 1.93 K |
| Cash Flow From Operations | (79 M) | 971.22 M |
| Short Ratio | 1.77 X | 4.00 X |
| Earnings Per Share | (1.36) X | 3.12 X |
| Target Price | 4.0 | |
| Number Of Employees | 66 | 18.84 K |
| Beta | 2.34 | -0.15 |
| Market Capitalization | 59.55 M | 19.03 B |
| Total Asset | 153.9 M | 29.47 B |
| Retained Earnings | (486.8 M) | 9.33 B |
| Working Capital | 117.18 M | 1.48 B |
| Net Asset | 153.9 M |
Note: Acquisition by Leonid Beigelman of 169500 shares of Aligos TherapeuticsInc at 1.34 subject to Rule 16b-3 [view details]
Aligos TherapeuticsInc Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Aligos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 12362.96 | |||
| Daily Balance Of Power | (0.57) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.77 | |||
| Day Typical Price | 0.76 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.04) |
About Aligos TherapeuticsInc Buy or Sell Advice
When is the right time to buy or sell Aligos TherapeuticsInc? Buying financial instruments such as Aligos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 14.5M | 12.6M | 11.1M | 10.6M | Total Assets | 235.4M | 146.7M | 153.9M | 193.5M |
Use Investing Ideas to Build Portfolios
In addition to having Aligos TherapeuticsInc in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hedge Favorites Thematic Idea Now
Hedge Favorites
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Aligos TherapeuticsInc Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Aligos Stock please use our How to Invest in Aligos TherapeuticsInc guide.Note that the Aligos TherapeuticsInc information on this page should be used as a complementary analysis to other Aligos TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Aligos Stock analysis
When running Aligos TherapeuticsInc's price analysis, check to measure Aligos TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos TherapeuticsInc is operating at the current time. Most of Aligos TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Aligos TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos TherapeuticsInc's price. Additionally, you may evaluate how the addition of Aligos TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Aligos TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos TherapeuticsInc. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.242 | Quarterly Revenue Growth (0.24) | Return On Assets (0.37) | Return On Equity (0.89) |
The market value of Aligos TherapeuticsInc is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Aligos TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos TherapeuticsInc's market value can be influenced by many factors that don't directly affect Aligos TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.